Cardiometabolic Risk FactorsCASNCT07363499
Combining Physical Activity and Sedentary Interventions to Improve Cardiometabolic Health
A study testing WHO physical activity guideline and Sedentary behaviour reduction at the workplace in people with Cardiometabolic Risk Factors and Sedentary Behaviors, run by Hasselt University at 1 site in Belgium.
Trial summary
Many adults spend a large part of their day sitting, especially at work. Long periods of sitting and not moving enough can increase the risk of health problems such as heart disease and type 2 diabetes. Read more about this study
- Who is it for?
- Ages 18 to 65 yearsHealthy volunteers can take part
- Conditions the study is for
- Cardiometabolic Risk Factors, Sedentary Behaviors, Insulin Resistance
- What is being tested?
- WHO physical activity guideline and Sedentary behaviour reduction at the workplace
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 30 participants
- Where
- 1 siteBelgium
- Study dates
- 28 Apr 2024to Feb 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Age 18 to 65 years
- Profession where most of the time is spent sitting.
- Not regularly physically active (>3 trainings per week in the last three months)
- Sedentary (on average >9 hours per day spent sedentary on a working day)
- Written informed consent to participate in the study.
Who cannot join
- Pregnancy.
- Consumption of more than 20 units of alcohol per week.
- Medical conditions that limit physical activity.
- Specific diet (e.g. low-carbohydrate or calorie-restricted).
- Unstable body weight in the past month.
- Participation in another study that could potentially affect your blood parameters in the past month.
Trial locations and contacts
1 site in 1 country.
About this study
Many adults spend a large part of their day sitting, especially at work. Long periods of sitting and not moving enough can increase the risk of health problems such as heart disease and type 2 diabetes. This risk is even higher in people who have early warning signs like being overweight, having high blood pressure, or problems with blood sugar. Together, these problems are called metabolic syndrome.
The goal of this study is to find out whether combining regular exercise with reducing sitting time during the day can improve heart and metabolic health more than exercise alone.
Read more
About 40 adults between 18 and 65 years old who work mainly at a desk and sit for more than 9 hours a day will take part. All participants will first continue their normal daily routine for two weeks. After that, they will be randomly placed into one of two groups for eight weeks:
Exercise group: Participants will follow the World Health Organization guidelines for physical activity. This includes two sessions of moderate exercise each week (such as brisk walking or cycling) and one session of more intense exercise each week.
Exercise plus less sitting group: Participants will do the same exercise program, but they will also be encouraged to sit less during the workday. They will be asked to stand more, use sit-stand desks if possible, and avoid sitting for longer than one hour at a time.
Participants will visit the research center three times for health tests. These tests include blood samples to look at blood sugar, insulin, and fats in the blood, measurements of blood pressure and heart function, body composition scans, fitness tests, and questionnaires about sleep, diet, and quality of life. They will also wear activity monitors to measure how much they sit, stand, and move.
The main outcome is how the body handles sugar (insulin sensitivity). The researchers hope to learn whether sitting less, in addition to exercising, leads to better improvements in heart and metabolic health. The results may help develop better lifestyle advice to prevent heart disease and diabetes in people with desk jobs.
- Being tested
- WHO physical activity guideline, Sedentary behaviour reduction at the workplace
- Keywords
- Cardiometabolic health, Sedentary behaviour, Physical activity, Exercise, Insulin resistance
- Medical subject headings
- Sedentary Behavior, Insulin Resistance, Motor Activity
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
WHO physical activity guidelineBehavioural
Individualised Physical Activity Plan (8 weeks):
- Two weekly sessions of moderate-intensity physical activity (MIPA): Frequency: 2 sessions per week. Unsupervised. Duration: Initially 40 minutes per session, increasing to 50 minutes by week 4. Type of Activity: Participants can select from brisk walking, cycling, swimming, or elliptical training.
Intensity: 40-60% of maximal oxygen consumption, monitored with wearable heart rate devices.
- One weekly session of vigorous-intensity physical activity (VIPA): Frequency: 1 session per week. Supervised or predetermined. Duration: Initially 20 minutes per session, increasing to 30 minutes by week 4. Type of Activity: Options include running, high-intensity interval training (HIIT), or fast cycling.
Intensity: 60-90% of maximal oxygen consumption, tracked with heart rate devices.
- Weekly check-ins will allow adjustments based on individual feedback and progress.
Sedentary behaviour reduction at the workplaceBehavioural
Participants will be encouraged to replace seated work with standing work and engage in light physical activity breaks.
- Workplace Integration Strategies: Participants working in an office setting will be provided with adjustable sit-stand desks where possible.
- Active Breaks and Movement Interventions: Participants will be prompted to take short (2min) active breaks after prolonged periods of sedentary behaviour.
Break activities will include standing, stretching, or light movement such as walking.
| Study group | Role | What they receive |
|---|---|---|
| Control arm (2 weeks) | No intervention | All participants will follow a two-week period where no intervention is administered. |
| PA group (8 weeks) | Active comparator | After the control period without intervention, one halve of the participants is randomised to the PA group where participants are encouraged to adhere to WHO physical activity guidelines during 8 weeks. Receives: Behavioral: WHO physical activity guideline |
| PA-SB group (8 weeks) | Experimental | After the control period without intervention, one halve of the participants is randomised to the PA-SB group where participants are encouraged to adhere to WHO physical activity guidelines. In addition, sedentary time at the workplace is reduced. The duration of this intervention is 8 weeks. Receives: Behavioral: WHO physical activity guideline; Behavioral: Sedentary behaviour reduction at the workplace |
What is being measured
The primary outcome is the main question the study is designed to answer.
Homeostatic model assessment for insulin resistance (HOMA-IR)
The HOMA-IR is calculated from the fasting insulin and glucose concentration.
Measured: From enrollment to the end of the intervention at 8 weeks.
Whole-body insulin sensitivity index (ISI)
An oral glucose tolerance test will be performed for assessment of whole body insulin sensitivity using the whole-body insulin sensitivity index (ISI). The ISI is calculated from both insulin and glucose concentrations.
Measured: From enrollment to the end of the intervention at 8 weeks
Area under the curve of insulin concentrations
An oral glucose tolerance test will be performed for assessment of whole body insulin sensitivity by calculation of the area under the curve of insulin concentrations.
Measured: From enrollment to the end of the intervention at 8 weeks
Insulinogenic index
An oral glucose tolerance test will be performed for assessment of beta cell function by calculation of the insulinogenic index. The insulinogenic index is calculated from both insulin and glucose concentrations.
Measured: From enrollment to the end of the intervention at 8 weeks.
Secondary outcomes (28)
Body composition
Body composition is evaluated by Dual-energy X-ray absorptiometry. Fat mass (in kg), lean body mass (in kg), body fat percentage (in %) and visceral adipose tissue (in grams) will be derived from the Dual-energy X-ray absorptiometry.
Measured: From enrollment to the end of the intervention at 8 weeks.
Cardiorespiratory Fitness
Cardiorespiratory fitness will be measured as peak oxygen consumption (V̇O2peak) using a graded cardiopulmonary exercise test (CPET) on a bike with pulmonary gas exchange analysis (Jaeger Oxycon®) until volitional exhaustion.
Measured: From enrollment to the end of the intervention at 8 weeks.
Area under the curve of glucose concentrations
An oral glucose tolerance test will be performed for assessment of whole body insulin sensitivity by calculation of the area under the curve of glucose concentrations.
Measured: From enrollment to the end of the intervention at 8 weeks
Steps per day
Physical activity will be quantified using the activPAL3™ activity monitor.
Measured: From enrollment to the end of the intervention at 8 weeks. For one week during the first four weeks of the intervention. For one week during the last four weeks of the intervention.
Sitting time
Sedentary behaviour will be quantified using the activPAL3™ activity monitor.
Measured: From enrollment to the end of the intervention at 8 weeks. For one week during the first four weeks of the intervention. For one week during the last four weeks of the intervention.
Moderate to vigorous physical activity
Physical activity will be quantified using the activPAL3™ activity monitor.
Measured: From enrollment to the end of the intervention at 8 weeks. For one week during the first four weeks of the intervention. For one week during the last four weeks of the intervention.
Light intensity physical activity
Physical activity will be quantified using the activPAL3™ activity monitor.
Measured: From enrollment to the end of the intervention at 8 weeks. For one week during the first four weeks of the intervention. For one week during the last four weeks of the intervention.
Sleep
Physical activity will be quantified using the activPAL3™ activity monitor.
Measured: From enrollment to the end of the intervention at 8 weeks. For one week during the first four weeks of the intervention. For one week during the last four weeks of the intervention.
Body weight
Body weight (in underwear) is determined using a digital-balanced weighting scale to the nearest 0.1kg
Measured: From enrollment to the end of the intervention at 8 weeks
Height
Body height is measured to the nearest 0.1cm using a wall-mounted Harpenden stadiometer, with participants barefoot
Measured: From enrollment to the end of the intervention at 8 weeks.
Body mass index
Body mass index (BMI; kg/m²) is calculated from weight and height measurements (weight/height²).
Measured: From enrollment to the end of the intervention at 8 weeks
Waist and hip circumference
Waist and hip circumferences will be measured to the nearest 0.1 cm using a flexible metric measuring tape with participants barefoot (in underwear) in standing position. Waist circumference is measured at the midpoint between the lower rib margin and the top of the iliac crest. Hip circumference is measured at the widest circumference of the hip at the level of the greater trochanter. Waist-to-hip ratio is calculated by dividing waist circumference (cm) by hip circumference (cm). Waist-to-height ratio is calculated by dividing waist circumference (cm) by height (cm).
Measured: From enrollment to the end of the intervention at 8 weeks
Blood pressure
After an initial resting period of 10 min with participants in a supine position in a quiet room with constant temperature (21°C), systolic and diastolic blood pressure (BP; in mmHg) will be measured at least 3 times at 2-min intervals until BP is stable using an electronic sphygmomanometer (Omron®) from the left arm and documented as the mean value of the three final measurements.
Measured: From enrollment to the end of the intervention at 8 weeks
Vascular endothelial function
Vascular function will be assessed by FMD according to published guidelines. These measurements take place at 9h and involve doppler ultrasound imaging of the superficial femoral artery. A cuff will be placed on the right lower leg, and the superficial femoral artery is imaged longitudinally. FMD will be measured at baseline and after a 5-min occlusion phase (reactive hyperaemia response). FMD will be quantified as the percentage difference between peak and baseline diameter (FMD%).
Measured: From enrollment to the end of the intervention at 8 weeks
Cardiac autonomic function
Cardiac autonomic function will be operationalized as heart rate variability by means of continuous beat-to-beat heart rate signal measurements. time domain and frequency domain analysis of the R-R intervals will be performed
Measured: From enrollment to the end of the intervention at 8 weeks
Concentration of glucose
Blood analysis
Measured: From enrollment to the end of the intervention at 8 weeks
Concentration of insulin
Blood analysis
Measured: From enrollment to the end of the intervention at 8 weeks.
Concentration of total cholesterol
Blood analysis
Measured: From enrollment to the end of the intervention at 8 weeks.
Concentration of Low-Density Lipoprotein cholesterol
Blood analysis
Measured: From enrollment to the end of the intervention at 8 weeks.
Concentration of High-Density Lipoprotein cholesterol
Blood analysis
Measured: From enrollment to the end of the intervention at 8 weeks.
Concentration of triglycerides
Blood analysis
Measured: From enrollment to the end of the intervention at 8 weeks.
Concentration of apolipoproteins
Blood analysis
Measured: From enrollment to the end of the intervention at 8 weeks.
Concentration of CRP
Blood analysis
Measured: From enrollment to the end of the intervention at 8 weeks.
Concentration of Interleukin 6 (IL-6)
Blood analysis
Measured: From enrollment to the end of the intervention at 8 weeks.
Concentration of interleukin 1 (IL-1)
Blood analysis
Measured: From enrollment to the end of the intervention at 8 weeks.
Sleep quality
Sleep quality over a period of one month will be assessed with the Pittsburgh sleep quality index (PSQI) which is a self-administered questionnaire consisting of 19 items that is reliable and valid to assess sleep problems.
Measured: From enrollment to the end of the intervention at 8 weeks.
Food intake
Habitual dietary intake is assessed using a validated food frequency questionnaire (FFQ). In addition, participants will fill in a diary to evaluate dietary intake either with an app or on paper.
Measured: From enrollment to the end of the intervention at 8 weeks
Quality of life (QOL)
Health-related quality of life (HRQOL) was measured using the Euroqol 5-D questionnaire (EQ-5D). The EQ-5D is a widely used and validated generic instrument consisting of five dimensions: mobility, self- care, usual activities, pain/discomfort and anxiety/depression.
Measured: From enrollment to the end of the intervention at 8 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted23 Jan 2026
- Study start28 Apr 2024
- Primary completionFeb 2026 (estimated)
- Study completionFeb 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Cardiometabolic Risk FactorsStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- First all participants will follow a control period after which they are randomised to a parallel design with two intervention groups.
- Masking
- None (open label)
- Enrolment
- 30 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Hasselt University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Bert Op't Eijnde, Hasselt University
- Investigators
- Jen Vanherle, MSc, Principal investigator, Hasselt University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07363499
- Sponsor's protocol ID
- CME2024/069
- Acronym
- CAS
- Status last verified
- Jan 2026
- First submitted
- 22 Dec 2025
- Last updated
- 23 Jan 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: In a restriced access depositry. Personal data is sensitive data and is thus protected in a restricted access repository. During the project these data will be pseudonymized and after completion of the project data will be anonymized and the pseudonymization key will be destroyed. Access can be granted by the primary investigator who holds the pseudonymization key in a restricted folder during the project.
Study at a glance
From the registry record, last updated by the sponsor on 23 Jan 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Combining Physical Activity and Sedentary Interventions to Improve Cardiometabolic Health
- ClinicalTrials.gov ID
- NCT07363499
- Acronym / sponsor ID
- CAS / CME2024/069
- Keywords
- Cardiometabolic health, Sedentary behaviour, Physical activity, Exercise, Insulin resistance
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 30 participants (estimated)
- Lead sponsor
- Hasselt UniversityUniversity, hospital or other
- Study start
- 28 Apr 2024 (actual)
- Primary completion
- Feb 2026 (estimated)
- Study completion
- Feb 2026 (estimated)
- First posted
- 23 Jan 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Many adults spend a large part of their day sitting, especially at work. Long periods of sitting and not moving enough can increase the risk of health problems such as heart disease and type 2 diabetes. This risk is even higher in people who have early warning signs like being overweight, having high blood pressure, or problems with blood sugar. Together, these problems are called metabolic syndrome.
The goal of this study is to find out whether combining regular exercise with reducing sitting time during the day can improve heart and metabolic health more than exercise alone.
About 40 adults between 18 and 65 years old who work mainly at a desk and sit for more than 9 hours a day will take part. All participants will first continue their normal daily routine for two weeks. After that, they will be randomly placed into one of two groups for eight weeks:
Exercise group: Participants will follow the World Health Organization guidelines for physical activity. This includes two sessions of moderate exercise each week (such as brisk walking or cycling) and one session of more intense exercise each week.
Exercise plus less sitting group: Participants will do the same exercise program, but they will also be encouraged to sit less during the workday. They will be asked to stand more, use sit-stand desks if possible, and avoid sitting for longer than one hour at a time.
Participants will visit the research center three times for health tests. These tests include blood samples to look at blood sugar, insulin, and fats in the blood, measurements of blood pressure and heart function, body composition scans, fitness tests, and questionnaires about sleep, diet, and quality of life. They will also wear activity monitors to measure how much they sit, stand, and move.
The main outcome is how the body handles sugar (insulin sensitivity). The researchers hope to learn whether sitting less, in addition to exercising, leads to better improvements in heart and metabolic health. The results may help develop better lifestyle advice to prevent heart disease and diabetes in people with desk jobs.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 3
- Model description
- First all participants will follow a control period after which they are randomised to a parallel design with two intervention groups.
| Arm | Type | Receives |
|---|---|---|
| Control arm (2 weeks) | No intervention | –All participants will follow a two-week period where no intervention is administered. |
| PA group (8 weeks) | Active comparator | Behavioral: WHO physical activity guidelineAfter the control period without intervention, one halve of the participants is randomised to the PA group where participants are encouraged to adhere to WHO physical activity guidelines during 8 weeks. |
| PA-SB group (8 weeks) | Experimental | Behavioral: WHO physical activity guideline, Behavioral: Sedentary behaviour reduction at the workplaceAfter the control period without intervention, one halve of the participants is randomised to the PA-SB group where participants are encouraged to adhere to WHO physical activity guidelines. In addition, sedentary time at the workplace is reduced. The duration of this intervention is 8 weeks. |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Age 18 to 65 years
- Profession where most of the time is spent sitting.
- Not regularly physically active (>3 trainings per week in the last three months)
- Sedentary (on average >9 hours per day spent sedentary on a working day)
- Written informed consent to participate in the study.
Key exclusion criteria (6 listed)
- Pregnancy.
- Consumption of more than 20 units of alcohol per week.
- Medical conditions that limit physical activity.
- Specific diet (e.g. low-carbohydrate or calorie-restricted).
- Unstable body weight in the past month.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| WHO physical activity guidelineIndividualised Physical Activity Plan (8 weeks): • Two weekly sessions of moderate-intensity physical activity (MIPA): Frequency: 2 sessions per week. Unsupervised. Duration: Initially 40 minutes per session, increasing to 50 minutes by week 4. Type of Activity: Participants can select from brisk walking, cycling, swimming, or elliptical training. Intensity: 40-60% of maximal oxygen consumption, monitored with wearable heart rate devices. • One weekly session of vigorous-intensity physical activity (VIPA): Frequency: 1 session per week. Supervised or predetermined. Duration: Initially 20 minutes per session, increasing to 30 minutes by week 4. Type of Activity: Options include running, high-intensity interval training (HIIT), or fast cycling. Intensity: 60-90% of maximal oxygen consumption, tracked with heart rate devices. • Weekly check-ins will allow adjustments based on individual feedback and progress. | Behavioural | PA group (8 weeks), PA-SB group (8 weeks) |
| Sedentary behaviour reduction at the workplaceParticipants will be encouraged to replace seated work with standing work and engage in light physical activity breaks. • Workplace Integration Strategies: Participants working in an office setting will be provided with adjustable sit-stand desks where possible. • Active Breaks and Movement Interventions: Participants will be prompted to take short (2min) active breaks after prolonged periods of sedentary behaviour. Break activities will include standing, stretching, or light movement such as walking. | Behavioural | PA-SB group (8 weeks) |
Primary outcome
Homeostatic model assessment for insulin resistance (HOMA-IR)
Time frame: From enrollment to the end of the intervention at 8 weeks.
The HOMA-IR is calculated from the fasting insulin and glucose concentration.
Whole-body insulin sensitivity index (ISI)
Time frame: From enrollment to the end of the intervention at 8 weeks
An oral glucose tolerance test will be performed for assessment of whole body insulin sensitivity using the whole-body insulin sensitivity index (ISI). The ISI is calculated from both insulin and glucose concentrations.
Area under the curve of insulin concentrations
Time frame: From enrollment to the end of the intervention at 8 weeks
An oral glucose tolerance test will be performed for assessment of whole body insulin sensitivity by calculation of the area under the curve of insulin concentrations.
Insulinogenic index
Time frame: From enrollment to the end of the intervention at 8 weeks.
An oral glucose tolerance test will be performed for assessment of beta cell function by calculation of the insulinogenic index. The insulinogenic index is calculated from both insulin and glucose concentrations.
28 secondary outcomes
Body composition
Time frame: From enrollment to the end of the intervention at 8 weeks.
Cardiorespiratory Fitness
Time frame: From enrollment to the end of the intervention at 8 weeks.
Area under the curve of glucose concentrations
Time frame: From enrollment to the end of the intervention at 8 weeks
Steps per day
Time frame: From enrollment to the end of the intervention at 8 weeks. For one week during the first four weeks of the intervention. For one week during the last four weeks of the intervention.
Sitting time
Time frame: From enrollment to the end of the intervention at 8 weeks. For one week during the first four weeks of the intervention. For one week during the last four weeks of the intervention.
Moderate to vigorous physical activity
Time frame: From enrollment to the end of the intervention at 8 weeks. For one week during the first four weeks of the intervention. For one week during the last four weeks of the intervention.
Light intensity physical activity
Time frame: From enrollment to the end of the intervention at 8 weeks. For one week during the first four weeks of the intervention. For one week during the last four weeks of the intervention.
Sleep
Time frame: From enrollment to the end of the intervention at 8 weeks. For one week during the first four weeks of the intervention. For one week during the last four weeks of the intervention.
Body weight
Time frame: From enrollment to the end of the intervention at 8 weeks
Height
Time frame: From enrollment to the end of the intervention at 8 weeks.
Body mass index
Time frame: From enrollment to the end of the intervention at 8 weeks
Waist and hip circumference
Time frame: From enrollment to the end of the intervention at 8 weeks
Blood pressure
Time frame: From enrollment to the end of the intervention at 8 weeks
Vascular endothelial function
Time frame: From enrollment to the end of the intervention at 8 weeks
Cardiac autonomic function
Time frame: From enrollment to the end of the intervention at 8 weeks
Concentration of glucose
Time frame: From enrollment to the end of the intervention at 8 weeks
Concentration of insulin
Time frame: From enrollment to the end of the intervention at 8 weeks.
Concentration of total cholesterol
Time frame: From enrollment to the end of the intervention at 8 weeks.
Concentration of Low-Density Lipoprotein cholesterol
Time frame: From enrollment to the end of the intervention at 8 weeks.
Concentration of High-Density Lipoprotein cholesterol
Time frame: From enrollment to the end of the intervention at 8 weeks.
Concentration of triglycerides
Time frame: From enrollment to the end of the intervention at 8 weeks.
Concentration of apolipoproteins
Time frame: From enrollment to the end of the intervention at 8 weeks.
Concentration of CRP
Time frame: From enrollment to the end of the intervention at 8 weeks.
Concentration of Interleukin 6 (IL-6)
Time frame: From enrollment to the end of the intervention at 8 weeks.
Concentration of interleukin 1 (IL-1)
Time frame: From enrollment to the end of the intervention at 8 weeks.
Sleep quality
Time frame: From enrollment to the end of the intervention at 8 weeks.
Food intake
Time frame: From enrollment to the end of the intervention at 8 weeks
Quality of life (QOL)
Time frame: From enrollment to the end of the intervention at 8 weeks
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 23 Jan 2026.
- Individual participant dataSharing planned: Yes. In a restriced access depositry. Personal data is sensitive data and is thus protected in a restricted access repository. During the project these data will be pseudonymized and after completion of the project data will be anonymized and the pseudonymization key will be destroyed. Access can be granted by the primary investigator who holds the pseudonymization key in a restricted folder during the project.
Related trials for Cardiometabolic Risk Factors
Not yet recruitingObservational study
A Natural History of Cardiometabolic Disease Among US Bhutanese: Developing the Cross-Sectional Bhutanese Community of Central Ohio Health Study to Understand Acculturation as Synergizing Socioenvironmental and Biobehavioral Risk Factors Propagating ...
Cardiometabolic Risk Factors, Mental Health
RecruitingObservational study
Asprosin and miRNA Expression in Young Women With Metabolic Syndrome
Metabolic Syndrome, Insulin Resistance
Not yet recruiting
Multimodal AI-Driven Out-of-Hospital Management for Hypertension and Cardiometabolic Risk
Hypertension, Hyperglycemia
Active, not recruiting
Trial of Pistachio Consumption in Older Adults
Cognition, Cardiometabolic Risk Factors
Active, not recruiting
Effect of a Ginger-Based Beverage on Inflammation, Oxidative Stress, and Endothelial Function
Inflammation Biomarkers, Oxidative Stress
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Jen Vanherle, MSc principal investigator
Hasselt University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing WHO physical activity guideline and Sedentary behaviour reduction at the workplace in people with Cardiometabolic Risk Factors and Sedentary Behaviors, run by Hasselt University at 1 site in Belgium.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 23 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Belgium. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Homeostatic model assessment for insulin resistance (HOMA-IR) (time frame: From enrollment to the end of the intervention at 8 weeks.). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Jan 2026.